Labcorp Holdings (LH) Cash & Equivalents (2009 - 2026)

Labcorp Holdings has reported Cash & Equivalents for 18 years, with the latest figure at $981.1 million in Q1 2026.

• Quarterly Cash & Equivalents rose 165.59% year-over-year to $981.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $981.1 million (up 165.59% YoY) and the FY2025 annual result came in at $532.3 million, down 64.95% from the prior year.
• Cash & Equivalents rose to $981.1 million in Q1 2026 per LH's latest filing, from $532.3 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $1.9 billion in Q2 2023 and troughed at $99.3 million in Q1 2024.
• A 5-year average of $773.6 million and a median of $598.1 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents slumped 86.27% in 2024, then jumped 272.0% in 2025.
• Over 5 years, Cash & Equivalents stood at $320.6 million in 2022, then surged by 67.44% to $536.8 million in 2023, then jumped by 182.92% to $1.5 billion in 2024, then slumped by 64.95% to $532.3 million in 2025, then jumped by 84.31% to $981.1 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $981.1 million, $532.3 million, and $598.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.